Hasil Pencarian - Fenghao Shi

  • Menampilkan 1 - 7 hasil dari 7
Perbaiki Hasil
  1. 1
    Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing

    Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness... oleh Yena Gan, Fenghao Shi, Fenghao Shi, He Zhu, He Zhu, Sheng Han, Sheng Han, Duoduo Li

    Diterbitkan 2023-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Cost-effectiveness of edaravone dexborneol versus edaravone for the treatment of acute ischemic stroke in China: Based on the TASTE study

    Cost-effectiveness of edaravone dexborneol versus edaravone for the treatment of acute ischemic stroke in China: Based on the TASTE study oleh Fenghao Shi, Fenghao Shi, Zixuan He, Zixuan He, Lin Wang, Hang Su, Hang Su, Sheng Han, Sheng Han

    Diterbitkan 2022-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China

    Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China oleh Fenghao Shi, Fenghao Shi, Zixuan He, Zixuan He, Hang Su, Hang Su, Lin Wang, Sheng Han, Sheng Han

    Diterbitkan 2022-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Cost-effectiveness of durvalumab plus tremelimumab in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer from the US healthcare sector’s and societal perspectives

    Cost-effectiveness of durvalumab plus tremelimumab in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer from the US healthcare sector’s and s... oleh Yena Gan, Fenghao Shi, Fenghao Shi, He Zhu, He Zhu, Huangqianyu Li, Huangqianyu Li, Sheng Han, Sheng Han, Duoduo Li

    Diterbitkan 2024-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    A Systematic Review of Methods and Study Quality of Economic Evaluations for the Treatment of Schizophrenia

    A Systematic Review of Methods and Study Quality of Economic Evaluations for the Treatment of Schizophrenia oleh Luying Wang, Luying Wang, Fenghao Shi, Fenghao Shi, Xin Guan, Xin Guan, He Xu, He Xu, Jing Liu, Hongchao Li, Hongchao Li

    Diterbitkan 2021-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Impacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysis

    Impacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysis oleh Yu Xie, Hua Xing, Zihao Wang, Hongbin Yi, Fenghao Shi, Liping Kuai, Dongyan Xu

    Diterbitkan 2023-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Will the Inducing and Maintaining Remission of Non-biological Agents and Biological Agents Differ for Crohn's Disease? The Evidence From the Network Meta-Analysis

    Will the Inducing and Maintaining Remission of Non-biological Agents and Biological Agents Differ for Crohn's Disease? The Evidence From the Network Meta-Analysis oleh Mingjun Rui, Mingjun Rui, Zhengyang Fei, Zhengyang Fei, Yingcheng Wang, Yingcheng Wang, Fenghao Shi, Fenghao Shi, Rui Meng, Rui Meng, Ye Shang, Ye Shang, Aixia Ma, Aixia Ma, Hongchao Li, Hongchao Li

    Diterbitkan 2021-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: